- The French partner VFP Therapies has developed innovative chemical entities which are improved prodrugs called Bioprecursors: they have the ability to easily go through the BBB and selectively act on specific receptors to induce therapeutic effects.
- Alzex currently holds two families of patents via an exclusive and unlimited licensing agreement with INSA (Institut National des Sciences Appliquées) a major French academic engineer and research institute.
- “Spending on care for people alive in the U.S. right now who will develop the affliction is projected to cost $47 trillion.“ – Another Alzheimer’s Drug Fails as Lilly, Astra Halt Tests, Bloomberg.
- Currently conducting preclinical trials and expect to enter phase 1 in one to two years
- Potential licensing arrangement opportunities for big pharmaceutical companies
- Has potential to be applied to other brain diseases such as Parkinson’s, dementia, schizophrenia, cancer, etc.
Alzex is a collaboration of researchers, scientists, and investors that have developed and patented precision therapeutics for the treatment of Alzheimer’s and other neurological diseases. Their North American headquarters is located in Vancouver B.C with their laboratories located in France (Normandy).
Life Science Technology
Alzex has devised an innovative therapeutic approach aimed at treating brain diseases by means of highly selective prodrugs. At the same time, Alzex also carries out contractual work on behalf of pharmaceutical and biotechnology companies. Such ancillary contracts may focus either on joined development work or on the provision of a service, specifically in the area of fighting the side effects of drugs for brain diseases.
- This new class of drugs does not deploy any biological activity before they have crossed the Blood Brain Barrier (BBB), and hence do not induce significant side effects.
- The therapy can then target specific receptor sites in a more selective way, forming a superior delivery system through the BBB. The validity of this approach is evidenced by their progress on Alzheimer’s disease. The company has developed and patented two families of this new class of drugs, of which they have “proof of concept” in animal trials (in-vivo).
- This technology can be applied to any number of brain diseases.
Dr. Francis Marsais VFP Therapies, Founder & CEO
- Francis Marsais, Ph.D. in Organic Chemistry
- Former director of an important academic research group within the
- Institut de Recherche en Chimie Organique Fine (13 years)
- Former director in charge of partnerships at the Institut National des
- Sciences Appliquées (5 years)
- Author of over 130 international papers and holds 5 patents
Dr. Vincent Gembus VFP Therapies, CSO
- Vincent Gembus, Ph.D in Organic Chemistry
- Manager of various R&D project in medicinal chemistry on behalf of pharmaceutical partners
- Author of high level international papers
- Very good experience of the pharmaceutical development
- Key leader of the R&D team